Lipoic acid

Generic Name: Lipoic acid

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₄O_₂S_₂

CAS Number: 1200-22-2

Unique Ingredient Identifier: VLL71EBS9Z

Background: A vitamin-like antioxidant.

Indication: For nutritional supplementation, also for treating dietary shortage or imbalance.

Associated Conditions: Diabetic Neuropathies, Type 2 Diabetes Mellitus

Associated Therapies: Dietary and Nutritional Therapies, Nutritional supplementation

Clinical Trials

The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy

Phase 4

Completed

Conditions: Cardiac Autonomic Neuropathy
Type 2 Diabetes

Interventions: Drug: α-lipoic acid

First Posted Date: 2014-02-06

Last Posted Date: 2014-02-06

Lead Sponsor: The Catholic University of Korea

Target Recruit Count: 91

Registration Number: NCT02056366

Locations: 🇰🇷
Eulji General Hospital, Seoul, Korea, Republic of
🇰🇷
The Catholic University of Korea, Seoul, Korea, Republic of
🇰🇷
Sejong General Hospital, Seoul, Korea, Republic of

Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes

Phase 4

Conditions: Acute Kidney Injury
The Changes of Plasma Creatinine
The Changes of Plasma Free Radicals
The Changes of Endothelium-dependent Arterial Dilation

Interventions: Drug: Alpha lipoic acid

First Posted Date: 2013-11-07

Last Posted Date: 2013-11-08

Lead Sponsor: Xiang Guang-da

Target Recruit Count: 200

Registration Number: NCT01978405

Locations: 🇨🇳
Wuhan General Hospital, Wuhan, Hubei, China

Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

Phase 4

Completed

Conditions: Left Ventricular Mass
Type 2 Diabetes
Coronary Artery Disease

Interventions: Drug: alpha-lipoic acid

First Posted Date: 2013-06-13

Last Posted Date: 2015-08-21

Lead Sponsor: Wuhan General Hospital of Guangzhou Military Command

Target Recruit Count: 66

Registration Number: NCT01877590

Locations: 🇨🇳
Wuhan General Hospital, Wuhan, Hubei, China

Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy

Phase 4

Completed

Conditions: Apical Ballooning Syndrome
Nervous System Diseases, Sympathetic

Interventions: Drug: Placebo
Drug: alpha-lipoic acid
Drug: L-acetyl carnitine

First Posted Date: 2012-02-02

Last Posted Date: 2016-01-27

Lead Sponsor: University of Campania "Luigi Vanvitelli"

Target Recruit Count: 90

Registration Number: NCT01524861

Locations: 🇮🇹
Dept Geriatric and Metabolic diseases SUN, Naples, Italy

A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants

Phase 2

Completed

Conditions: Adrenomyeloneuropathy

Interventions: Drug: N-acetylcysteine
Drug: lipoic acid
Drug: vitamin E

First Posted Date: 2011-12-19

Last Posted Date: 2019-03-11

Lead Sponsor: Pujol, Aurora, M.D.

Target Recruit Count: 13

Registration Number: NCT01495260

Locations: 🇪🇸
Hospital Universitari de Bellvitge, L'Hospitalet de LLobregat, Barcelona, Spain

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Phase 4

Terminated

Conditions: NASH (Non-alcoholic Steato-hepatitis)

Interventions: Drug: Rosiglitazone
Drug: alpha-lipoic acid
Drug: Rosiglitazone/alpha-lipoic acid

First Posted Date: 2011-08-01

Last Posted Date: 2011-08-19

Lead Sponsor: Seoul St. Mary's Hospital

Target Recruit Count: 26

Registration Number: NCT01406704

Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

Phase 1

Completed

Conditions: Peripheral Neuropathy

Interventions: Drug: Alpha lipoic acid

First Posted Date: 2011-03-11

Last Posted Date: 2014-10-02

Lead Sponsor: Northwestern University

Target Recruit Count: 9

Registration Number: NCT01313117

Locations: 🇺🇸
Northwestern Medical Faculty Foundation, Chicago, Illinois, United States

Lipoic Acid as a Treatment for Acute Optic Neuritis

Phase 1

Completed

Conditions: Optic Neuritis

Interventions: Drug: Lipoic Acid

First Posted Date: 2011-02-11

Last Posted Date: 2019-04-26

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 31

Registration Number: NCT01294176

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy

Phase 2

Conditions: Diabetics

Interventions: Other: Placebo
Drug: lipoic acid

First Posted Date: 2010-10-20

Last Posted Date: 2010-10-21

Lead Sponsor: NovaMed Pharmaceuticals Inc.

Target Recruit Count: 200

Registration Number: NCT01224353

Locations: 🇨🇳
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳
Wuxi No.2 People's Hospital, Wuxi, Jiangsu, China
🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China

and more 2 locations

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

Phase 2

Completed

Conditions: Multiple Sclerosis, Chronic Progressive

Interventions: Drug: lipoic acid
Drug: Placebo

First Posted Date: 2010-08-26

Last Posted Date: 2017-02-02

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 54

Registration Number: NCT01188811

Locations: 🇺🇸
VA Portland Health Care System, Portland, OR, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy